Business
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
New investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the
About this update from Phathom Pharmaceuticals, Inc.
[{"type":"text","content":"New investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the treatment of Helicobacter pylori (H. pylori) infection Phathom research recognized with multiple “posters of distinction” by American Gastroenterological Association (AGA) Institute FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), an innovative biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the company will present findings from multiple studies at Digestive Disease Week® (DDW) 2022, being held May 21-24 in person in San Diego, CA and virtually. The clinical data from Phathom being presented during the congress include Phase 3 results evaluating vonoprazan as investigational monotherapy in erosive esophagitis (EE) and data on the pharmacodynamics and pharmacokinetics of vonoprazan compared to lansoprazole, a proton pump inhibitor. An analysis of H. pylori diagnosis and treatment patterns will also be presented, among other important clinical developments. “The breadth of data being presented at this year’s DDW highlights Phathom’s continued commitment to improving the lives of patients affected by acid-related gastrointestinal disorders,” said Eckhard Leifke, M.D., Chief Medical Officer at Phathom. “We look forward to sharing new data that explores unmet medical needs, as well as important analyses of treatment patterns and healthcare resource utilization. We are also excited that key data evaluating vonoprazan will be highlighted in several posters of distinction and in oral presentations.” In addition to seven poster sessions and two oral presentations, Phathom will also have a physical presence on the exhibit floor at booth #1731 and throughout the conference. See below for full list of scientific data being presented on behalf of Phathom at DDW 2022. Phathom’s Scientific Presentations at DDW 2022 Sunday, May 22, 2022 Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in Healthy U.S. Subjects 12:30 PM to 1:30 PM PDTPresentation #: Su1202Poster Session (Poster of Distinction*) Novel Approach to Evaluate the Impact of Moderate and Strong CYP3A Inducers on Vonoprazan ...